Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
P53 and TLR4 expression are prognostic markers informing progression free survival of advanced stage high grade serous ovarian cancer.
Bates M, Mullen D, Lee E, Costigan D, Heron EA, Kernan N, Barry-O'Crowley J, Martin C, Keegan H, Malone V, Brooks RD, Brooks DA, Logan JM, Martini C, Selemidis S, McFadden J, O'Riain C, Spillane CD, Gallagher MF, McCann A, O'Toole S, O'Leary JJ. Bates M, et al. Among authors: gallagher mf. Pathol Res Pract. 2024 Jan;253:155020. doi: 10.1016/j.prp.2023.155020. Epub 2023 Dec 7. Pathol Res Pract. 2024. PMID: 38103365 Free article.
Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer.
Furlong F, Fitzpatrick P, O'Toole S, Phelan S, McGrogan B, Maguire A, O'Grady A, Gallagher M, Prencipe M, McGoldrick A, McGettigan P, Brennan D, Sheils O, Martin C, W Kay E, O'Leary J, McCann A. Furlong F, et al. J Pathol. 2012 Apr;226(5):746-55. doi: 10.1002/path.3035. Epub 2012 Jan 17. J Pathol. 2012. PMID: 22069160 Free PMC article.
The MyD88+ phenotype is an adverse prognostic factor in epithelial ovarian cancer.
d'Adhemar CJ, Spillane CD, Gallagher MF, Bates M, Costello KM, Barry-O'Crowley J, Haley K, Kernan N, Murphy C, Smyth PC, O'Byrne K, Pennington S, Cooke AA, Ffrench B, Martin CM, O'Donnell D, Hennessy B, Stordal B, Finn S, McCann A, Gleeson N, D'Arcy T, Flood B, O'Neill LA, Sheils O, O'Toole S, O'Leary JJ. d'Adhemar CJ, et al. Among authors: gallagher mf. PLoS One. 2014 Jun 30;9(6):e100816. doi: 10.1371/journal.pone.0100816. eCollection 2014. PLoS One. 2014. PMID: 24977712 Free PMC article.
The role of the MAD2-TLR4-MyD88 axis in paclitaxel resistance in ovarian cancer.
Bates M, Spillane CD, Gallagher MF, McCann A, Martin C, Blackshields G, Keegan H, Gubbins L, Brooks R, Brooks D, Selemidis S, O'Toole S, O'Leary JJ. Bates M, et al. Among authors: gallagher mf. PLoS One. 2020 Dec 28;15(12):e0243715. doi: 10.1371/journal.pone.0243715. eCollection 2020. PLoS One. 2020. PMID: 33370338 Free PMC article.
CD10-/ALDH- cells are the sole cisplatin-resistant component of a novel ovarian cancer stem cell hierarchy.
Ffrench B, Gasch C, Hokamp K, Spillane C, Blackshields G, Mahgoub TM, Bates M, Kehoe L, Mooney A, Doyle R, Doyle B, O'Donnell D, Gleeson N, Hennessy BT, Stordal B, O'Riain C, Lambkin H, O'Toole S, O'Leary JJ, Gallagher MF. Ffrench B, et al. Among authors: gallagher mf. Cell Death Dis. 2017 Oct 19;8(10):e3128. doi: 10.1038/cddis.2017.379. Cell Death Dis. 2017. PMID: 29048400 Free PMC article.
Circulating tumour cell enumeration does not correlate with Miller-Payne grade in a cohort of breast cancer patients undergoing neoadjuvant chemotherapy.
O'Toole SA, Spillane C, Huang Y, Fitzgerald MC, Ffrench B, Mohamed B, Ward M, Gallagher M, Kelly T, O'Brien C, Ruttle C, Bogdanska A, Martin C, Mullen D, Connolly E, McGarrigle SA, Kennedy J, O'Leary JJ. O'Toole SA, et al. Breast Cancer Res Treat. 2020 Jun;181(3):571-580. doi: 10.1007/s10549-020-05658-7. Epub 2020 May 6. Breast Cancer Res Treat. 2020. PMID: 32378053 Free PMC article.
27 results